Beebe, Timothy

Dent, John

Johnsson, Folke

Junghard, Ola

Lind, Tore

Shaw, Michael

Wiklund, Ingela

English

PubMed

Background: Critical needs for treatment trials in gastroesophageal reflux disease (GERD) include assessing response to treatment, evaluating symptom severity, and translation of symptom questionnaires into multiple languages. We evaluated the previously validated Reflux Disease Questionnaire (RDQ) for internal consistency, reliability, responsiveness to change during treatment and the concordance between RDQ and specialty physician assessment of symptom severity, after translation into Swedish and Norwegian. Methods: Performance of the RDQ after translation into Swedish and Norwegian was evaluated in 439 patients with presumed GERD in a randomized, double-blind trial of active treatment with a proton pump inhibitor. Results: The responsiveness was excellent across three RDQ indicators. Mean change scores in patients on active treatment were large, also reflected in effect sizes that ranged from a low of 1.05 (dyspepsia) to a high of 2.05 (heartburn) and standardized response means 0.99 (dyspepsia) and 1.52 (heartburn). A good positive correlation between physician severity ratings and RDQ scale scores was seen. The internal consistency reliability using alpha coefficients of the scales, regardless of language, ranged from 0.67 to 0.89. Conclusion: The results provide strong evidence that the RDQ is amenable to translation and represents a viable instrument for assessing response to treatment, and symptom severity.Michael Shaw, John Dent, Timothy Beebe, Ola Junghard, Ingela Wiklund, Tore Lind and Folke Johnsso

Shaw, M.

Dent, J.

Beebe, T.

Junghard, O.

Wiklund, I.

Lind, T.

Johnsson, F.

Adelaide Research & Scholarship

Health and Quality of Life Outcomes

The Reflux Disease Questionnaire: a measure for assessment of treatment response in clinical trials

Michael Shaw

John Dent

Timothy Beebe

Ola Junghard

Ingela Wiklund

Tore Lind

Folke Johnsson

Springer - Publisher Connector

Background: Critical needs for treatment trials in gastroesophageal reflux disease (GERD) include assessing response to treatment, evaluating symptom severity, and translation of symptom questionnaires into multiple languages. We evaluated the previously validated Reflux Disease Questionnaire (RDQ) for internal consistency, reliability, responsiveness to change during treatment and the concordance between RDQ and specialty physician assessment of symptom severity, after translation into Swedish and Norwegian. Methods: Performance of the RDQ after translation into Swedish and Norwegian was evaluated in 439 patients with presumed GERD in a randomized, double-blind trial of active treatment with a proton pump inhibitor. Results: The responsiveness was excellent across three RDQ indicators. Mean change scores in patients on active treatment were large, also reflected in effect sizes that ranged from a low of 1.05 (dyspepsia) to a high of 2.05 (heartburn) and standardized response means 0.99 (dyspepsia) and 1.52 (heartburn). A good positive correlation between physician severity ratings and RDQ scale scores was seen. The internal consistency reliability using alpha coefficients of the scales, regardless of language, ranged from 0.67 to 0.89. Conclusion: The results provide strong evidence that the RDQ is amenable to translation and represents a viable instrument for assessing response to treatment, and symptom severity

Lund University Publications

Abstract Background Critical needs for treatment trials in gastroesophageal reflux disease (GERD) include assessing response to treatment, evaluating symptom severity, and translation of symptom questionnaires into multiple languages. We evaluated the previously validated Reflux Disease Questionnaire (RDQ) for internal consistency, reliability, responsiveness to change during treatment and the concordance between RDQ and specialty physician assessment of symptom severity, after translation into Swedish and Norwegian. Methods Performance of the RDQ after translation into Swedish and Norwegian was evaluated in 439 patients with presumed GERD in a randomized, double-blind trial of active treatment with a proton pump inhibitor. Results The responsiveness was excellent across three RDQ indicators. Mean change scores in patients on active treatment were large, also reflected in effect sizes that ranged from a low of 1.05 (dyspepsia) to a high of 2.05 (heartburn) and standardized response means 0.99 (dyspepsia) and 1.52 (heartburn). A good positive correlation between physician severity ratings and RDQ scale scores was seen. The internal consistency reliability using alpha coefficients of the scales, regardless of language, ranged from 0.67 to 0.89. Conclusion The results provide strong evidence that the RDQ is amenable to translation and represents a viable instrument for assessing response to treatment, and symptom severity.</p

Junghard Ola

Beebe Timothy

Dent John

Shaw Michael

Wiklund Ingela

Lind Tore

Johnsson Folke

Directory of Open Access Journals

Crossref

Coefficient alpha and the internal structure of tests. Psychometrika

Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines.

Department of Health and Human Services, Food and Drug Administration: Guidance for Industry. Patient reported outcome measures: use in medical product development to support labeling claims.

Epstein RS: Interpretation of quality of life changes. Qual Life Res

GR: Health measurement scales: a practical guide to their development and use 2nd edition.

Guyatt G: Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials

Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease.

L: Endoscopic assessment of esophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut

LE: Determining a minimal important change in a disease-specific quality of life questionnaire.

One-week esomeprazole treatment: an effective confirmatory test in patients with suspected gastroesophageal reflux disease.

Reliability and validity Assessment.

Revicki DA: Assessing symptoms in gastroesophageal reflux disease: how well do clinicians' assessments agree with those of their patients?

RF: Effect sizes for interpreting changes in health status. Med Care

RS: Interpreting treatment effects in randomized trials. BMJ

Statistical power analysis for the behavioral sciences

Symptomrelieving effect of esomeprazole 40 mg daily in patients with heartburn.

Vakil N: Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs. Gut

http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2390523

The Reflux Disease Questionnaire: a measure for assessment of treatment response in clinical trials

Abstract

Similar works

Full text

Available Versions

Adelaide Research & Scholarship

Springer - Publisher Connector

Lund University Publications

Directory of Open Access Journals

Crossref

Springer - Publisher Connector